Skip to main content

Chronic Ulcer of Leg or Foot

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Tissue Repair
Tissue RepairAustralia - Sydney
1 program
CACIPLIQ20®N/A1 trial
Active Trials
NCT05170984Completed191Est. Dec 2024
ConvaTec
ConvaTecNJ - Bridgewater
1 program
ConvaFoamN/A1 trial
Active Trials
NCT05632250Completed95Est. Mar 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
ConvaTecConvaFoam
Tissue RepairCACIPLIQ20®

Clinical Trials (2)

Total enrollment: 286 patients across 2 trials

A Prospective, Multi Centre, Interventional, Non-comparator, Open Label Study to Demonstrate the Efficacy, Safety, and Performance of ConvaFoam™ Dressings in the Management of Indicated Chronic Wound Types.

Start: Apr 2023Est. completion: Mar 202495 patients
N/ACompleted

MAtrix Therapy for Hard-to-heal ChrOnic Wounds

Start: Feb 2022Est. completion: Dec 2024191 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.